Schizophrenia Research
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Complex chronic conditions among children born to women with schizophrenia.
241:24-35.
2022
-
Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis.
226:84-94.
2020
-
You say “schizophrenia” and I say “psychosis”: Just tell me when I can come off this medication.
225:39-46.
2020
-
Anxiety in youth at clinical high risk for psychosis: A case study and conceptual model.
208:441-446.
2019
-
Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.
208:202-208.
2019
-
Corrigendum to “Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder” [Schizophr. Res. 193 (2018) 173–181].
204:462-463.
2019
-
N400 event-related brain potential evidence for semantic priming deficits in persons at clinical high risk for psychosis.
204:434-436.
2019
-
The relation of vitamin D, metabolic risk and negative symptom severity in people with psychotic disorders.
195:513-518.
2018
-
Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder.
193:173-181.
2018
-
Peripheral biomarker signatures of bipolar disorder and schizophrenia: A machine learning approach.
188:182-184.
2017
-
Mental illness in patients with inherited mitochondrial disorders.
187:33-37.
2017
-
Characterizing outcome preferences in patients with psychotic disorders: a discrete choice conjoint experiment.
185:107-113.
2017
-
Intranasal delivery of antipsychotic drugs.
184:2-13.
2017
-
Differences in parental bonding between schizophrenia and bipolar disorder: Evidence of prodromal symptoms?.
165:134-137.
2015
-
Corrigendum to “Test–retest reliability of N400 event-related brain potential measures in a word-pair semantic priming paradigm in patients with schizophrenia” [Schizophr. Res. 158 (2014) 195–203].
160:235-235.
2014
-
Factors contributing to the duration of untreated psychosis.
158:76-81.
2014
-
Improving functional outcomes for schizophrenia patients in the Netherlands using Cognitive Adaptation Training as a nursing intervention — A pilot study.
158:120-125.
2014
-
Test–retest reliability of N400 event-related brain potential measures in a word-pair semantic priming paradigm in patients with schizophrenia.
158:195-203.
2014
-
Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data.
154:54-60.
2014
-
Neurocognition, functional capacity, and functional outcomes: The cost of inexperience.
152:430-434.
2014
-
Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review.
152:408-414.
2014
-
Stability and change in symptoms, cognition, and community outcome in schizophrenia.
152:435-439.
2014
-
The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): Preliminary evidence for reliability and validity.
150:410-415.
2013
-
A brief version of the Subjects' Response to Antipsychotics questionnaire to evaluate treatment effects.
147:175-180.
2013
-
Human blood analysis reveals differences in gene expression of catecholamine-regulated protein 40 (CRP40) in schizophrenia.
143:203-206.
2013
-
Hashimoto encephalopathy diagnosis after 40years of a schizophrenia-like disorder.
139:269-270.
2012
-
Behavioral effects of non-viral mediated RNA interference of synapsin II in the medial prefrontal cortex of the rat.
137:32-38.
2012
-
Disconnected and underproductive speech in schizophrenia: Unique relationships across multiple indicators of social functioning.
131:152-156.
2011
-
Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: Examining synapsin II in the pathophysiology of schizophrenia.
130:250-259.
2011
-
Exploring logical reasoning abilities in schizophrenia patients.
127:178-180.
2011
-
PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: Implications for the treatment of negative symptoms in schizophrenia.
125:88-92.
2011
-
Atypical antipsychotic drugs upregulate synapsin II in the prefrontal cortex of post-mortem samples obtained from patients with schizophrenia.
120:229-231.
2010
-
Antipsychotic drug use is correlated with CRP40/mortalin mRNA expression in the dorsolateral prefrontal cortex of human postmortem brain specimens.
119:228-231.
2010
-
"TURN IT UP TO 11": THE RELATIONSHIP BETWEEN BRAIN NOISE AND LEARNING IN SCHIZOPHRENIA.
117:347-348.
2010
-
Decreased tooth size in schizophrenia.
110:194-196.
2009
-
Psychopathology and cognition in divergent functional outcomes in schizophrenia.
109:46-51.
2009
-
Decomposing perseverative errors among undergraduates scoring high on the Schizotypal Personality Questionnaire.
106:3-12.
2008
-
EXPLORING THE NEURAL CORRELATES OF DELUSIONS OF REFERENCE: AN fMRI STUDY.
102:90-90.
2008
-
Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?.
99:149-154.
2008
-
Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia.
97:292-293.
2007
-
Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study.
96:215-222.
2007
-
Inconsistency in the relationship between duration of untreated psychosis (DUP) and negative symptoms: Sorting out the problem of heterogeneity.
93:152-159.
2007
-
The University of California Performance Skills Assessment (UPSA) in schizophrenia.
88:135-141.
2006
-
Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes.
81:29-39.
2006
-
Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium.
74:111-119.
2005
-
Shyness, sociability, and social dysfunction in schizophrenia.
48:343-349.
2001
-
Manual performance in leukotomized and unleukotomized individuals with schizophrenia.
17:267-278.
1995
-
SCHIZOPHRENIA AND THE COCHRANE-COLLABORATION.
13:185-187.
1994
-
Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients.
11:33-40.
1993
-
Introduction.
11:1-2.
1993
-
Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by position emission tomography (PET).
11:47-54.
1993
-
17. Neuroleptic effects on regional brain metabolism in first episode schizophrenics.
5:208-209.
1991
-
Neuroleptic drug effects on cognitive function in schizophrenia.
3:211-219.
1990
-
Apomorphine effects on brain metabolism in neuroleptic naive first episode schizophrenics and normal controls.
3:25-25.
1990
-
Substance abuse and schizophrenia: Effects on symptoms but not on neurocognitive function.
3:65-65.
1990
-
Poster #M85 VERBAL EPISODIC MEMORY IMPAIRMENT ALONG THE COURSE OF SCHIZOPHRENIA AND BIPOLAR DISORDER
2014
-
Poster #T120 DOES RTMS HELP TO IMPROVE NEGATIVE SYMPTOMS IN SCHIZOPHRENIA? RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN THE NETHERLANDS
2014
-
Poster #T194 IMPROVING FUNCTIONAL OUTCOMES FOR SCHIZOPHRENIA PATIENTS IN THE NETHERLANDS USING COGNITIVE ADAPTATION TRAINING AS A NURSING INTERVENTION – A PILOT STUDY
2014
-
Poster #T96 MEASURING THE GAP BETWEEN COGNITION AND FUNCTIONING: EVALUATING AWARENESS OF THE BRIDGE BETWEEN COGNITION AND EVERYDAY BEHAVIOUR VIA THE ASSESSMENT OF BRIDGING STRATEGIES OF THINKING TO REAL-WORLD ACTIVITIES (ABSTRACT)
2014
-
RISK OF SYMPTOM RECURRENCE WITH MEDICATION DISCONTINUATION IN FIRST-EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW
2014
-
Poster #153 NEUROCOGNITIVE PROFILING IN A LARGE COHORT OF FIRST EPISODE PATIENTS SUGGESTS THREE SPECIFIC SUBGROUPS
2012
-
Poster #167 A VIRTUAL REALITY INVESTIGATION OF SPONTANEOUS NAVIGATION STRATEGIES IN SCHIZOPHRENIA
2012
-
Poster #205 DEVELOPMENT OF A BRIEF QUESTIONNAIRE FOR (UN)DESIRED EFFECTS OF ANTIPSYCHOTICS
2012
-
Poster #248 EVALUATING PATIENT PREFERENCES FOR EARLY INTERVENTION SERVICES USINGDISCRETE CHOICE CONJOINTANALYSIS
2012
-
Poster #67 COGNITIVE EXCEPTIONALITY AND IMPAIRMENT IN SCHIZOPHRENIA
2012
-
ISSUES REGARDING GENETIC TESTING FOR SCHIZOPHRENIA RISK AND FOR ANTIPSYCHOTIC DRUG EFFECTS
2010
-
0223 SUBSTANCE USE AND ABUSE IN FIRST EPISODE PSYCHOSIS: PREVALENCE BEFORE AND AFTER EARLY INTERVENTION
2006
-
0366 SCOTTISH STUDY OF PSYCHOSIS: ENGAGEMENT, ATTACHMENT AND RECOVERY (SSP: EAR)- STUDY OUTLINE
2006
-
0472 DURATION OF UNTREATED PSYCHOSIS AND OUTCOME: APPLICATION OF LATENT CLASS REGRESSION ANALYSES
2006
-
Alpha4 and beta2 genetic interaction. analysis of high affinity nicotinic receptor in schizophrenia
2006
-
Association study between smoking and high affinity nicotinic receptor subunit genes in schizophrenia patients
2006
-
Predictors of outcome from first episode psychosis in Ontario, Canada
2006
-
Readiness to change eating habits and physical activity in patients with affective psychosis and schizophrenia spectrum disorders
2006
-
Abnormal movements in first-episode psychosis patients
2004
-
Disability and need in adolescent onset psychosis
2004
-
Examining the outcome of first-episode psychosis: A meta-analysis of prospective studies
2004
-
First-episode psychosis, substance abuse and early intervention
2004
-
Quality of life and first-episode psychosis patients
2004
-
The Ontario longitudinal study of first episode psychosis
2004
-
A computational model of the role of dopamine and psychotropic drugs in modulating motivated action
2003
-
Depressive symptoms and course identify two distinct clusters within very poor outcome schizophrenia
2003
-
Patterns of visual processing in schizophrenia: Selective dorsal pathway impairment
2003
-
The effect of single-dose risperidone on aromatic amino acid decar☐ylase activity in healthy human subjects measured using [18F]6-fluoro-L-M-tyrosine positron emission tomography
2003
-
Combined event-related potential and functional neuroimaging methods for investigation of working memory deficits in patients with first episode schizophrenia and related disorders
2001
-
Improvement in cogntive functioning in patients with first episode psychosis after treatment with quetiapine
2001
-
A brain-specific 14-3-3 protein gene, YWHAH, is mutation screened in two schizophrenic families from the intermountain west
1999
-
Placebo-controlled trials:
1999
-
Distribution of ventricular brain ratio values in schizophrenic patients and normal subjects
1996
-
1H NMR spectroscopy of the human brain in vivo: The hippocampus in schizophrenic patients and normals
1995
-
Functional magnetic resonance imaging of the motor cortex in schizophrenia: Procedures and initial observations
1995
-
Regional brain glucose metabolism in neuroleptic naive first episode and chronic schizophrenic patients and normal controls at rest and after dopamine agonist and antagonist drugs
1991
-
INCREASED FRONTAL AND REDUCED PARIETAL GLUCOSE-METABOLISM IN ACUTE UNTREATED SCHIZOPHRENIA
1988
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)